The problem may not be your pipeline. Before you invest in another solution, prove what is actually limiting growth.
SHELA helps leadership teams diagnose which commercial reality deserves intervention first, then decide where scarce resources should go based on evidence.
A full pipeline, a busy sales team, and healthy CRM activity can coexist with stalled growth, margin pressure, forecast volatility, or too many competing priorities.
The same visible symptom can come from different underlying realities: leadership, company, product, customer or market conditions, or the way resources are being prioritized and executed. More activity can amplify the wrong problem if the diagnosis is wrong.
More execution does not solve a problem you have not correctly diagnosed.
Weak growth, stalled accounts, forecast volatility, margin pressure, or too many priorities can share the same surface symptoms while requiring very different interventions.
Commercial Decision Precision starts with the problem, not the provider.
SHELA examines four connected realities: Personal / Leadership, Company, Product, and Customer / Market. The value is in understanding where they align, where they do not, and what that means for the commercial decision.
Only after the diagnosis is clear should leadership decide the appropriate countermeasure, where resources deserve to go, and who should lead the next intervention.
The result: greater confidence about what deserves intervention first, what evidence supports the decision, and what should happen next.
You need more than another sales push.
SHELA is built for leadership teams that know more activity is not the same as better commercial decisions and want to establish the root problem before committing more resources.
- You are tired of explaining another poor quarter when your pipeline looked full and your team stayed busy.
- You suspect the visible sales problem may not be the root cause and want evidence before choosing another intervention.
- You are watching strategic accounts slow down, stall, or move to competitors after months of expensive internal work.
- Your leadership team does not fully trust which deals are real, which are weak, and which should never have entered the forecast.
- Your sales cycle is long, inconsistent, or harder to predict, and the organization is not aligned on what is causing the drag.
- Sales, marketing, product, finance, and leadership are working from different assumptions about what deserves priority.
- You have CRM, intent data, ABM tools, AI tools, or lead-generation activity, but no shared decision discipline for interpreting the evidence and deciding what deserves intervention.
- You need a credible growth plan grounded in commercial reality, resource trade-offs, forecast confidence, and evidence-backed priorities.
Diagnose what deserves intervention. Then decide where resources deserve to go.
The immediate value is better decision clarity. Downstream operating and financial outcomes depend on the issue identified, the chosen countermeasure, company fit, data quality, leadership commitment, and execution.
Establish what problem deserves intervention first and what evidence supports the conclusion before committing larger resources.
Make explicit trade-offs about where sales, marketing, product, technical, finance, and executive attention should be concentrated.
When prioritization is the material constraint, apply evidence-backed selection logic to improve the quality of the accounts and opportunities receiving disproportionate investment.
Improve visibility into buyer evidence, execution risk, and changing conditions so leadership can reassess before the quarter is already lost.
Give cross-functional leaders a shared evidence base, decision criteria, and language for challenging assumptions and resolving trade-offs.
Proceed, resolve another issue first, redirect to a different intervention, or reconsider further investment based on what the diagnosis supports.
Not a campaign. Not a workshop. Not CRM cleanup.
If Phase 1 evidence shows that commercial prioritization and account selection are the material next constraint, Phase 2 applies SHELA's Commercial Decision System to decide where disproportionate resources deserve to go.
Inside-Out
Examine historical account and product economics, strengths, constraints, and patterns that reveal where the business has created value and where assumptions may be misleading.
Outside-In
Evaluate market attractiveness, customer trajectory, competitive context, and unmet opportunity so internal history is tested against external reality.
Targeted Accounts
Apply shared evidence-based criteria to determine which accounts deserve disproportionate commercial investment and which should be deprioritized.
Dashboard + Decision Intelligence
Monitor buyer commitment, execution risk, controlled exceptions, and changing evidence so leadership knows when to continue, adapt, or reassess.
A repeatable decision discipline, not a one-time account list.
When Phase 1 warrants it, Phase 2 combines inside-out evidence, outside-in market and customer reality, targeted-account choices, and decision intelligence so leadership can decide where to invest, where to stop, and what evidence would change the decision.
SHELA System™
Analysis
Alignment
Plan
Dashboard
Continuous improvement
Built from 25+ years inside B2B commercial transformation.
The SHELA System™ was created by Helith Sofer, founder of SHELA Commercial Strategy, after more than 25 years inside B2B strategic marketing, sales operations, product strategy, business development, and commercial transformation roles across Fortune 200 and mid-market companies.
Founder proof: National Accounts at a B2B industrial manufacturing Fortune 200 company
What: Before founding SHELA Commercial Strategy, Helith built the original matchmaking-style national account playbook inside an industrial business where national accounts had declined for five years, eight National Account Managers were stretched across 135 chain concepts, average deal cycles were 30 months, and the close rate was only 10%.
Why it mattered: The business did not need another generic sales initiative. It needed a sharper way to reduce a 135-account universe into the accounts most likely to win, then concentrate expensive pre-sales, technical, sales, and executive effort where it could change growth.
Outcome: The playbook cut the customer acquisition process from 30 months to 18 months and increased the close rate from 10% to 22%, a 120% improvement. That field-tested logic is the foundation of the SHELA System™.
Take the High Command Assessment.
This is not a generic lead form. It is a short executive fit assessment designed to test strategic fit, economic significance, decision urgency, and organizational readiness before either side invests time in the wrong conversation.
Take High Command Assessment NowA staged decision architecture, not an automatic consulting program.
Each step earns the next decision, not the next sale. Phase 1 stands on its own and determines what the evidence justifies next.
High Command Assessment
Short fit assessment that routes the right executive to the appropriate conversation.
Strategy Mapping
3-week independent Decision Gate. Possible outcomes: PROCEED, RESOLVE FIRST, REDIRECT, or RECONSIDER.
Phase 2 When Warranted
12-week Commercial Decision System only when Phase 1 evidence supports prioritization / account selection as the material next constraint.
Phase 3 When Authorized
Implementation and operating-cadence support only after approved decisions and a separately authorized path.
What leadership teams usually ask before they apply.
Is this consulting, sales training, RevOps, ABM, CRM, or AI?
No. Those disciplines typically improve execution, tools, campaigns, or processes. SHELA works one decision earlier: what problem deserves intervention first, what evidence should guide that decision, and where scarce commercial resources should go once the diagnosis is clear.
Is this lead generation?
No. Lead generation focuses on creating more demand or more names in the funnel. SHELA focuses on commercial decision quality: whether the underlying opportunity, market, customer, product, and leadership realities justify where resources are being concentrated in the first place.
How is this different from ABM?
ABM typically begins after a target-account decision has already been made. SHELA starts earlier by testing whether that decision is sound, what evidence supports it, and whether account prioritization is even the right problem to solve. If it is, Phase 2 can then establish where disproportionate commercial investment belongs.
Why do we need the High Command Assessment?
Because this work is not right for every company. The assessment tests strategic fit, economic significance, decision urgency, executive value, organizational readiness, and ability to act before either side spends time on the wrong conversation.
Will the High Command Assessment take too long?
No. It is designed to take about 4 minutes and includes 8 executive-level questions across strategic fit, economic significance, urgency, consequence, decision quality, executive value, organizational readiness, and ability to act.
We already have CRM, intent data, and sales tools. Why would we need this?
Tools provide information. SHELA helps leadership determine what that information means for the commercial decision: what problem is material, what assumptions need to be challenged, what evidence is missing, and where resources should go once the diagnosis is clear.
Our sales team already knows the market. Is this still useful?
Yes. The issue is often not individual knowledge. The challenge is whether leadership shares the same evidence, assumptions, and decision criteria about what deserves attention, what should change, and where resources should be concentrated.
Will this replace our sales process?
No. SHELA does not replace the sales process. It helps leadership improve the decisions that sit upstream of it: what deserves intervention, what evidence supports the priority, and where scarce commercial resources should be concentrated.
Who needs to be involved?
A rigorous diagnosis usually requires executive sponsorship plus access to the leaders and evidence needed to understand the commercial reality. Depending on the issue, that may include sales, marketing, product, finance, technical, RevOps, or other cross-functional leaders.
What results should we expect?
The immediate outcome is greater decision clarity: what problem deserves intervention, what evidence supports the conclusion, and what should happen next. Where the work proceeds into portfolio and implementation decisions, intended business outcomes may include stronger resource allocation, better portfolio quality, improved forecast confidence, and more disciplined commercial execution. Actual results depend on the client situation, decisions, and execution.
What if we are not ready for the full deployment?
Strategy Mapping is not a smaller version of a full deployment. It is an independent Decision Gate designed to establish what problem deserves intervention, what the evidence supports, and what should happen next. That may mean proceeding, resolving another issue first, redirecting to a different intervention, or reconsidering the need for further work.
How much longer can your team afford to invest before proving what problem deserves intervention?
When the root problem is unclear, more activity can consume sales, marketing, product, technical, finance, and executive capacity without improving the decision. Start by establishing what the evidence supports, then decide what deserves investment next.
Take the 8-question High Command Assessment